FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
pharmaceutical investing FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma
Finlay Minerals: Advancing Strategic Copper-Gold-Silver Assets in British Columbia’s Toodoggone District
Sun Summit Commences 2025 Exploration Program at the JD Project, Toodoggone District, British Columbia